Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Fellowship - Priority Announcement: Gastroenterology

University of Alberta

$45,000.00

Evaluation of the diagnostic value of chemokine and cytokine biomarkers and their role in the pathogenesis of autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC)

EF 2012-13

Résumé
Primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), and autoimmune hepatitis (AIH) are three common chronic inflammatory liver diseases (combined prevalence of ~1/1000) that account for a significant number of liver transplantations in North America (PSC is within the top five diseases requiring liver transplantation). The diagnosis of these conditions is suboptimal, invasive and expensive. Furthermore, in the majority of cases, significant liver injury has already occurred by the time of a confirmed diagnosis. In our initial study involving 313 individuals, we have recently identified a novel set of serum markers in patient blood samples that could improve diagnosis substantially. In the current proposal, we will attempt to confirm our serum-based tests using a larger patient cohort derived from national and international patients and investigate the role of these immune markers in the underlying mechanism of disease. Our overall goal is to identify better methods to diagnose such patients and from a better understanding of the mechanism of disease to identify new therapeutic avenues.
Programme
Fellowship - Priority Announcement: Gastroenterology
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
270569
Name
Landi Abdolamir
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Canadian Association of Gastroenterology (Oakville, Ontario); Takeda Canada Inc. (Mississauga, Ontario)
Instname2
Infection and Immunity
Theme2
Clinical
Prcname2
Fellowships - Post-PhD
Projecttitle
Evaluation of the diagnostic value of chemokine and cytokine biomarkers and their role in the pathogenesis of autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC)
Programtype2
Fellowship Programs
Orgnameinp2
University of Alberta
Cihramount2
$45,000
Cihrequipment2
$0
Programname2
Fellowship - Priority Announcement: Gastroenterology
Keyworddelim
& Immunohistochemistry; Animal Models & Therapeutic Intervention; Autoimmune Hepatitis & Pathogenesis; Cell Cultures; Cellular Immunology & Flow Cytometry; Chemokines & Receptors; Cytokines; Dna/Rna Purification & Rt-Pcr; Gasteroenterology & Hepatology; Immunostaining; Liver Biopsy; Molecular Biology; Primary Biliary Cirrhosis; Primary Sclerosing Cholangitis; Serological Diagnostics Biomarkers
Abstract
Primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), and autoimmune hepatitis (AIH) are three common chronic inflammatory liver diseases (combined prevalence of ~1/1000) that account for a significant number of liver transplantations in North America (PSC is within the top five diseases requiring liver transplantation). The diagnosis of these conditions is suboptimal, invasive and expensive. Furthermore, in the majority of cases, significant liver injury has already occurred by the time of a confirmed diagnosis. In our initial study involving 313 individuals, we have recently identified a novel set of serum markers in patient blood samples that could improve diagnosis substantially. In the current proposal, we will attempt to confirm our serum-based tests using a larger patient cohort derived from national and international patients and investigate the role of these immune markers in the underlying mechanism of disease. Our overall goal is to identify better methods to diagnose such patients and from a better understanding of the mechanism of disease to identify new therapeutic avenues.
Competitiondate
201210
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Landi, Abdolamir
Approvedterm
2 ans 0 mois
Cihrcontribution2
Patient Oriented Research~ $45,000~ $0~